The First Light: Efficacy and Safety of a Multi-Dose Study of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist for the Treatment of Narcolepsy Type 1

Sleep Medicine 2026

View at publisher
Authors: E. Mignot, I. Arnulf, G. Plazzi, R. del Rio Víllegas, R. Khatami, G.J. Lammers, M. Taniguchi, H. Kadali, Y. Du, S. Hsiao, T. Olsson, S. Sheikh
+3 more C. von Hehn, M.R. Etherton, Y. Dauvilliers
DOI: 10.1016/j.sleep.2025.107565
Cited by: 2

Fields of Study & Subjects

Sleep and Wakefulness Research Sleep and Work-Related Fatigue Restless Legs Syndrome Research

Publication details

Journal / source
Sleep Medicine
Publisher
Elsevier BV
Volume
138
Pages
107565–107565
Publication date
29 January 2026
Language
EN